Prolactin and erectile dysfunction have a more complicated relationship than the familiar connection between testosterone and sexual function. Prolactin is best known for supporting milk production, but men also produce it in small amounts through the pituitary gland. When levels rise substantially, sexual desire can decline, testosterone signaling may be suppressed, and erections may become less reliable. Still, elevated prolactin is an uncommon explanation for erectile dysfunction overall, and a single abnormal blood test does not establish that it is the cause.
What Prolactin Does in Men
Prolactin is a peptide hormone released by specialized cells in the anterior pituitary. Its secretion is normally restrained by dopamine from the hypothalamus, which is why medications that block dopamine can raise prolactin. Levels vary with sleep, stress, exercise, meals, sexual activity, and the timing and conditions of a blood draw.
In men, prolactin appears to participate in reproductive signaling, libido, and the post-orgasm refractory period. Physiologic concentrations are not harmful; the clinical concern is persistent hyperprolactinemia, meaning prolactin remains above the laboratory reference range after temporary influences and testing errors have been considered.
Excess prolactin can reduce hypothalamic secretion of gonadotropin-releasing hormone. That can lower luteinizing hormone and follicle-stimulating hormone output from the pituitary, which in turn reduces testosterone production by the testes. This is called hypogonadotropic hypogonadism. The possible symptoms extend beyond erection quality and may include reduced sexual desire, fewer spontaneous or morning erections, infertility, reduced body hair, breast enlargement, fatigue, or loss of bone density.
The pattern is not universal. Some men with marked hyperprolactinemia retain testosterone within the reference range, while others with only a modest elevation have symptoms for unrelated reasons. Prolactin must therefore be interpreted alongside testosterone, symptoms, medications, thyroid and kidney function, and the broader clinical picture.
How Prolactin and Erectile Dysfunction May Be Connected
The strongest established pathway is indirect: persistently high prolactin suppresses the reproductive hormone axis, testosterone falls, sexual desire decreases, and erectile function may deteriorate. Low desire matters because an erection is not simply a hydraulic reflex. Central arousal initiates neural signals that stimulate nitric oxide release and relaxation of penile smooth muscle. If central sexual signaling is diminished, even structurally healthy blood vessels may not receive a sufficient trigger.
Research also suggests that prolactin may affect erection independently of testosterone. A 2025 translational study combined clinical observations in men with pituitary tumors, an animal model, and cultured endothelial cells. Elevated prolactin was associated with worse erectile function despite normal testosterone in some patients. In the experimental models, prolactin suppressed the PI3K-Akt-eNOS pathway, which is involved in endothelial nitric oxide production. Lowering prolactin restored erectile responses and endothelial nitric oxide synthase expression in the animals [1].
That mechanistic result is important but should not be overextended. Much of the direct vascular work was conducted in rats and cells, not in a randomized human treatment trial. It supports biological plausibility rather than proving that a mildly elevated prolactin result causes erectile dysfunction in an otherwise healthy man.
The best contemporary clinical synthesis is similarly cautious. Corona and colleagues analyzed 25 studies and a large sexual-medicine clinic population. Hyperprolactinemia occurred in roughly 2% of men presenting with erectile dysfunction in the meta-analytic data. Higher prolactin showed a consistent relationship with lower sexual desire, and treating the elevation substantially improved libido. The effect on erections was less complete: prolactin and reduced testosterone were independently associated with erectile dysfunction rates, but normalizing prolactin only partially restored erectile function across the evidence base [2].
Causes and Clues That Make Testing More Relevant
A prolactin-secreting pituitary adenoma, or prolactinoma, is the most recognized cause of clinically significant hyperprolactinemia. These tumors are usually benign, but larger lesions can compress nearby structures. Headache, loss of peripheral vision, unexplained low testosterone, infertility, or breast discharge alongside sexual symptoms deserves medical evaluation.
Medication-related elevations are more common than prolactinomas in many settings. Dopamine-blocking antipsychotics, some antidepressants, certain anti-nausea drugs, opioids, and a smaller group of other medicines can raise prolactin. A medication should never be stopped abruptly based on a suspected hormone effect. The prescribing clinician can assess dose, timing, alternatives, and the risks of changing treatment.
Primary hypothyroidism can increase thyrotropin-releasing hormone and stimulate prolactin release. Chronic kidney disease may reduce prolactin clearance. Liver disease, chest-wall injury, seizures, and other pituitary or hypothalamic conditions are additional possibilities. Laboratory artifacts also matter. Macroprolactin is a large, less biologically active prolactin complex that can produce a high reported value with few or no symptoms.
For these reasons, indiscriminate screening of every man with erection difficulty has a low yield. Testing becomes more informative when erectile dysfunction is accompanied by low libido, a low morning testosterone result, infertility, gynecomastia, galactorrhea, headache, visual symptoms, or exposure to a medication known to elevate prolactin.
Prolactin and Erectile Dysfunction Testing: What an Abnormal Result Means
Evaluation usually begins with a careful history, physical examination, and a morning total testosterone measurement when hormonal symptoms are present. If testosterone is low, clinicians often add luteinizing hormone, follicle-stimulating hormone, and prolactin to distinguish a testicular problem from reduced signaling by the hypothalamus or pituitary.
A mild prolactin elevation commonly needs confirmation. The repeat sample may be collected under standardized conditions after the patient has rested, because stress from exercise, travel, or venipuncture can transiently increase the result. The clinician may also review thyroid function, kidney function, medication exposure, and macroprolactin. Extremely high concentrations are more suggestive of a prolactinoma, although assay behavior and drug effects can complicate interpretation.
Persistent, unexplained hyperprolactinemia may prompt pituitary magnetic resonance imaging and formal visual-field testing, particularly when the elevation is substantial or neurological symptoms are present. Diagnosis should not be inferred from erectile dysfunction alone.
The clinical numbers illustrate why context matters. In a 2024 cohort of 39 men with lactotroph adenomas, 22 had erectile dysfunction at diagnosis. Those with erectile dysfunction had lower testosterone and a higher prevalence of hypogonadism. After treatment and an average follow-up of approximately six years, 16 of those 22 men, or 73%, experienced remission of erectile dysfunction [3]. This shows that correction of a clear endocrine disorder can be meaningful, but the specialized tumor population cannot be used to predict results for men with ordinary multifactorial erectile dysfunction.
Treatment Depends on the Cause, Not the Number Alone
When a prolactinoma is responsible, dopamine agonists such as cabergoline are commonly used to lower prolactin and reduce tumor size. Surgery is considered in selected cases, including intolerance or resistance to medication, tumor characteristics, or individual patient priorities. A 2024 review of male prolactinomas emphasized that men often present later and with larger tumors than women, making timely recognition of sexual, reproductive, visual, and neurological symptoms important [4].
Medication-induced hyperprolactinemia requires coordination with the clinician managing the underlying condition. Options may include observing a mild asymptomatic elevation, adjusting the dose, or substituting a medication, but the psychiatric or medical consequences of a change can outweigh the hormone issue. Hypothyroidism, kidney disease, and other systemic causes need their own targeted management.
Erectile dysfunction may persist after prolactin and testosterone normalize because erections are influenced by cardiovascular disease, diabetes, obesity, smoking, neurological function, pelvic anatomy, relationship factors, and performance anxiety. The 2024 meta-analysis found that sexual desire responded more consistently to prolactin treatment than erection quality [2]. Persistent symptoms therefore warrant a standard erectile dysfunction assessment rather than an assumption that endocrine treatment has failed.
PDE5 inhibitors may support penile blood flow in appropriate patients, but they do not treat a pituitary tumor or correct hyperprolactinemia. Conversely, correcting prolactin does not guarantee resolution when vascular or psychological contributors remain. Effective care can require both treatment of the endocrine cause and a separate, physician-guided approach to erectile function.
Conclusion
Prolactin is a clinically important but uncommon contributor to erectile dysfunction. Marked, persistent elevation can suppress testosterone, reduce libido, and possibly interfere directly with endothelial nitric oxide signaling. The evidence is strongest for an effect on sexual desire; the effect on erections is variable and often overlaps with metabolic, vascular, medication-related, and psychological factors. Testing is most useful when erection difficulty appears with low libido, low testosterone, infertility, breast symptoms, headaches, visual changes, or a relevant medication history. An abnormal result should be confirmed and investigated rather than treated in isolation.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised EPIQ CHEWS treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can also review additional evidence-based men's health articles in the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Zhang X, et al. Prolactin impairs erectile function via eNOS suppression independently of testosterone. Toxicology and Applied Pharmacology. 2025;504:117532. doi:10.1016/j.taap.2025.117532
Corona G, Rastrelli G, Bianchi N, et al. Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire. International Journal of Impotence Research. 2024;36(4):324-332. doi:10.1038/s41443-023-00717-1
Andereggen L, Tortora A, Schubert GA, et al. Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma. Acta Neurochirurgica. 2024;166(1):314. doi:10.1007/s00701-024-06213-9
Duskin-Bitan H, Shimon I. Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment. Frontiers in Endocrinology. 2024;15:1338345. doi:10.3389/fendo.2024.1338345
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.